dorzolamide (trusopt) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Dorzolamide is marketed under the trade name Trusopt, indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP). TRUSOPT Ophthalmic Solution contains dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II. Following topical ocular administration, TRUSOPT reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.3990 - $7.4520

Australia

$6.0861
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( dorzolamide (trusopt), timolol (blocadren) - other name: cosopt pf )

Alternative names

4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4h-thieno(2,3-b)thiopyran-2-sulfonamide | 4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide | 4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide | (4s,6s)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide | 4s,6s-dorzolamide | (4s-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | (4s,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4h-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide | 5,6-dihydro-4-ethylamino-6-methyl-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | cosopt | cosopt pf | de-111 | dorzant | dorzolamid | dorzolamida | dorzolamide | dorzolamide chibret | dorzolamide hcl | dorzolamide hydrochloride | dorzolamide maleate | dorzolamide, (trans)-isomer | dorzolamidum | l 671152 | l-671,152 | mk0507 | mk 507 | mk-507 | trusopt

Organizations (89)

Research & Development (60)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (2)


 

Glaucoma, Open-Angle

Ocular Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Blood Pressure (Phase 2)

Corneal Diseases (Phase 4)

Exfoliation Syndrome (Phase 4)

Eye Diseases (Phase 4)

Glaucoma ()

Glaucoma, Open-Angle ()

Macular Degeneration (Phase 2/Phase 3)

Macular Edema (Phase 2/Phase 3)

Ocular Hypertension (Phase 4)

Retinal Degeneration (Phase 4)

Retinal Vein Occlusion (Phase 2)

Wet Macular Degeneration (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 72
  • # of Trial Organizations: 60

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue